Bazbek Davletov

Dr. Bazbek Davletov

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MMMaria Maiarú
Maria Maiarú
CLCharlotte Leese
Charlotte Leese
Michelangelo CertoMichelangelo Certo
Michelangelo Certo
IEIrene Echeverria-Altuna
Irene Echeverria-Altuna
AMAntonina S. Mangione
Antonina S. Mangione
SHStephen P. Hunt
Stephen P. Hunt
Silencing key neurons with botulinum toxin conjugates exerts long-lasting pain relief in mouse models of chronic pain.

20 September 2013 in Bioconjugate Chemistry
Verified
Journal Article
Open access
Enrico FerrariEnrico Ferrari
Enrico Ferrari
CGChunjing Gu
Chunjing Gu
DNDhevahi Niranjan
Dhevahi Niranjan
Laura RestaniLaura Restani
Laura Restani
CRChristine Rasetti-Escargueil
Christine Rasetti-Escargueil
BDBazbek Davletov
Bazbek Davletov
Clostridial neurotoxins reversibly block neuronal communication for weeks and months. While these proteolytic neurotoxins hold great promise for clinical applications and the investigation of brain function, their paralytic activity at neuromuscular junctions is a stumbling block. To redirect the clostridial activity to neuronal populations other than motor neurons, we used a new self-assembling method to combine the botulinum type A protease with the tetanus binding domain, which natively targets central neurons. The two parts were produced separately and then assembled in a site-specific way using a newly introduced ‘protein stapling’ technology. Atomic force microscopy imaging revealed dumbbell shaped particles which measure ∼23 nm. The stapled chimera inhibited mechanical hypersensitivity in a rat model of inflammatory pain without causing either flaccid or spastic paralysis. Moreover, the synthetic clostridial molecule was able to block neuronal activity in a defined area of visual cortex. Overall, we provide the first evidence that the protein stapling technology allows assembly of distinct proteins yielding new biomedical properties.

20 May 2013 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
JAJason Arsenault
Jason Arsenault
Enrico FerrariEnrico Ferrari
Enrico Ferrari
DNDhevahi Niranjan
Dhevahi Niranjan
SCSabine A. G. Cuijpers
Sabine A. G. Cuijpers
CGChunjing Gu
Chunjing Gu
BDBazbek Davletov
Bazbek Davletov
Precise cellular targeting of macromolecular cargos has important biotechnological and medical implications. Using a recently established ‘protein stapling’ method, we linked the proteolytic domain of botulinum neurotoxin type A (BoNT/A) to a selection of ligands to target neuroendocrine tumor cells. The botulinum proteolytic domain was chosen because of its well‐known potency to block the release of neurotransmitters and hormones. Among nine tested stapled ligands, the epidermal growth factor was able to deliver the botulinum enzyme into pheochromocytoma PC12 and insulinoma Min6 cells; ciliary neurotrophic factor was effective on neuroblastoma SH‐SY5Y and Neuro2A cells, whereas corticotropin‐releasing hormone was active on pituitary AtT‐20 cells and the two neuroblastoma cell lines. In neuronal cultures, the epidermal growth factor‐ and ciliary neurotrophic factor‐directed botulinum enzyme targeted distinct subsets of neurons whereas the whole native neurotoxin targeted the cortical neurons indiscriminately. At nanomolar concentrations, the retargeted botulinum molecules were able to inhibit stimulated release of hormones from tested cell lines suggesting their application for treatments of neuroendocrine disorders.

27 October 2017 in Toxins
Verified
Journal Article
Open access
PDF file
ARAleksander Rust
Aleksander Rust
LPLynda J. Partridge
Lynda J. Partridge
BDBazbek Davletov
Bazbek Davletov
GHGuillaume Hautbergue
Guillaume Hautbergue
Ribosome inactivating proteins (RIPs) form a class of toxins that was identified over a century ago. They continue to fascinate scientists and the public due to their very high activity and long-term stability which might find useful applications in the therapeutic killing of unwanted cells but can also be used in acts of terror. We will focus our review on the canonical plant-derived RIPs which display ribosomal RNA N-glycosidase activity and irreversibly inhibit protein synthesis by cleaving the 28S ribosomal RNA of the large 60S subunit of eukaryotic ribosomes. We will place particular emphasis on therapeutic applications and the generation of immunotoxins by coupling antibodies to RIPs in an attempt to target specific cells. Several generations of immunotoxins have been developed and we will review their optimisation as well as their use and limitations in pre-clinical and clinical trials. Finally, we endeavour to provide a perspective on potential future developments for the therapeutic use of immunotoxins.

9 November 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ARAleksander Rust
Aleksander Rust
CDCiara Doran
Ciara Doran
RHRosalyn Hart
Rosalyn Hart
TBThomas Binz
Thomas Binz
PSPaul Stickings
Paul Stickings
BDBazbek Davletov
Bazbek Davletov
Botulinum neurotoxins (BoNT) type A and type B are commonly used as biopharmaceutics for neurological diseases, uniquely allowing months-long paralysis of target muscles. Their exquisite neuronal specificity is conferred by a multistep process of binding, internalisation, cytosolic escape and cleavage of the neuron-specific proteins, SNAP-25 and vesicle-associated membrane proteins (VAMPs), ultimately to inhibit secretion of neurotransmitters. Currently the mouse lethality bioassay is the only available method for quality control testing of VAMP-cleaving botulinum products. Refined assays for botulinum product testing are urgently needed. Specifically, in vitro replacement assays which can account for all steps of BoNT intoxication are in high demand. Here we describe a novel SiMa cell-based approach where re-engineering of the VAMP molecule allows detection of all BoNT/B intoxication steps using a luminescent enzymatic reaction with sensitivity comparable to mouse LD50 bioassay. The presented one-step enzyme-linked immunosorbent assay meets 3Rs (Replacement, Reduction and Refinement of the use of animals) objectives, is user-friendly and will accelerate development of new botulinum drugs. The sensitive enzymatic reporter cell line could also be adapted for the detection of toxin activity during the manufacture of botulinum and tetanus vaccines.

21 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ARAleksander Rust
Aleksander Rust
CLCharlotte Leese
Charlotte Leese
TBThomas Binz
Thomas Binz
BDBazbek Davletov
Bazbek Davletov
Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells